Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.
Journal Paper/Review - Sep 20, 2022
Boesing Maria, Abig Kristin, Brändle Michael, Brutsche Martin, Burri Emanuel, Frye BjöC, Giezendanner Stéphanie, Grutters Jan C, Haas Philippe, Heisler Justian, Jaun Fabienne, Leuppi-Taegtmeyer Anne Barbara, Lüthi-Corridori Giorgia, Müller-Quernheim Joachim, Nüesch Reto, Pohl Wolfgang, Rassouli Frank, Leuppi Jörg D
Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disease courses still represent a threat, especially to patients with risk factors. This indicates the need for alternative strategies to prevent respiratory complications like acute respiratory distress syndrome (ARDS) associated with COVID-19. Aviptadil, a synthetic form of human vasoactive intestinal peptide, might be beneficial for COVID-19 patients at high risk of developing ARDS because of its ability to influence the regulation of exaggerated pro-inflammatory proteins and orchestrate the lung homeostasis. Aviptadil has recently been shown to considerably improve the prognosis of ARDS in COVID-19 when applied intravenously. An inhaled application of aviptadil has the advantages of achieving a higher concentration in the lung tissue, fast onset of activity, avoiding the hepatic first-pass metabolism, and the reduction of adverse effects. The overall objective of this project is to assess the efficacy and safety of inhaled aviptadil in patients hospitalized for COVID-19 at high risk of developing ARDS.